# A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

> **NCT05822843** · PHASE1 · COMPLETED · sponsor: **Shanghai Escugen Biotechnology Co., Ltd** · enrollment: 13 (actual)

## Conditions studied

- B-cell Lymphoid Malignancies

## Interventions

- **DRUG:** ESG206

## Key facts

- **NCT ID:** NCT05822843
- **Lead sponsor:** Shanghai Escugen Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-02
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-01-22
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822843, "A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05822843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*